Exploring Utilities and Outcomes With Infliximab Therapy

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 8, 2006, Pages 976-978

  Inadomi, John M ^a,b   Terdiman, Jonathan ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; INFLIXIMAB;

CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG USE; EDITORIAL; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INFECTION; LYMPHOMA; MEDICAL DECISION MAKING; MORBIDITY; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; REGISTER; REMISSION; RISK ASSESSMENT; SEPSIS; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; DECISION SUPPORT TECHNIQUES; GASTROINTESTINAL AGENTS; HUMANS; LYMPHOMA; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; REMISSION INDUCTION; RISK ASSESSMENT; SEPSIS;

EID: 33746377928     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.05.023     Document Type: Editorial

References (9)

1. Siegel C.A., Hur C., Korzenik J.R., et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 4 (2006) 1017-1024
2. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease. the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
3. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
4. Lichtenstein G.R., Yan S., Bala M., et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 99 (2004) 91-96
5. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infections and mortality in association with therapies for Crohn's disease. TREAT registry. Clin Gastroenterol Hepatol 4 (2006) 621-630
6. Agrawal A., Durrani S., Leiper K., et al. Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease. Clin Gastroenterol Hepatol 3 (2005) 1215-1220
7. Schwartz L.K., Kim M.K., Coleman M., et al. Case report. lymphoma arising in an ileal pouch anal anastamosis after immunomodulatory therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 4 (2006) 1030-1034
8. Rubenstein J.H., Chong R.Y., and Cohen R.D. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 35 (2002) 151-156
9. Bodger K. Economic implications of biological therapies for Crohn's disease. review of infliximab. Pharmacoeconomics 23 (2005) 875-888